Teva Pharma (TEVA) Reports In-Line Q2 EPS; Lowers Revenue Outlook

Teva Pharma (NYSE: TEVA) reported Q2 EPS of $0.59, in-line with the analyst estimate of $0.59. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $4.04 billion.

GUIDANCE:

Teva Pharma sees FY2021 EPS of $2.50-$2.70, versus the consensus of $2.45. Teva Pharma sees FY2021 revenue of $16-16.4 billion, versus prior of $16.4-$16.8 billion and the consensus of $16.55 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Teva submits NDA for ecopipam to treat pediatric Tourette syndrome
• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance